Changes in microRNA expression associated with metastasis and survival in patients with uveal melanoma
Metrics: PDF 601 views | Full Text 814 views | ?
Ayushi Vashishtha1, Tae Jin Lee1, Ashok Sharma1 and John J. Wallbillich1,2,3
1 Center for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA
2 Department of Obstetrics and Gynecology, Medical College of Georgia, Augusta University, Augusta, GA, USA
3 Current address: Department of Oncology, Wayne State University College of Medicine, Detroit, MI, USA
|John J. Wallbillich,||email:||email@example.com|
Keywords: uveal melanoma; metastasis; survival; microRNA; biomarker
Received: December 21, 2019 Accepted: March 19, 2020 Published: April 21, 2020
Uveal melanoma (UM) is a major intraocular cancer that is molecularly distinct from cutaneous melanoma. Approximately half of patients with UM eventually develop metastasis. The prognosis of metastatic UM is poor, with a median overall survival (OS) of less than a year. In this study, we sought to identify microRNAs (miRNAs) associated with metastasis and OS in UM. We analyzed the miRNA expression and clinical outcomes data from The Cancer Genome Atlas (TCGA) dataset for UM. Differential expression analyses were conducted for each miRNA with respect ever-development of metastasis. Multiple survival analyses were done, using the Cox proportional hazards model, to evaluate interactions between miRNA expression, metastasis, and OS. A total of 22 miRNAs (3 upregulated and 19 downregulated) were differentially expressed between patients with vs. without metastatic UM. These 22 miRNAs could be grouped into four clusters based on similarities in expression patterns. Of the 22 miRNAs differentially expressed with respect to metastasis, 21 were significantly associated with OS. The expression of multiple miRNAs was significantly associated with metastasis and overall survival in patients with UM. Further investigation of these miRNAs as biomarkers and/or therapeutic targets is warranted in the push to improve outcomes for patients with metastatic UM.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.